-
公开(公告)号：US20200000935A1
公开(公告)日：2020-01-02
申请号：US16542381
申请日：2019-08-16
Applicant: ModernaTX, Inc.
Inventor： Joshua P. FREDERICK , Ailin BAI
IPC: A61K48/00 , A61K38/17 , C07K14/705 , A61P35/00 , A61K45/06
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
-
公开(公告)号：US20190105280A1
公开(公告)日：2019-04-11
申请号：US16219418
申请日：2018-12-13
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Ailin BAI , Vladimir PRESNYAK , Stephen HOGE , Kerry BENENATO , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Susannah HEWITT
IPC: A61K9/51 , A61K9/00 , C07K14/54 , A61K38/17 , A61K38/20 , C07K14/705 , A61P35/00 , A61K39/395
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20180318229A1
公开(公告)日：2018-11-08
申请号：US15995889
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Ailin BAI , Vladimir PRESNYAK , Stephen HOGE , Kerry BENENATO , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Susannah HEWITT
IPC: A61K9/51 , A61P35/00 , A61K38/20 , A61K38/17 , C07K14/54 , C07K14/705 , A61K39/395 , A61K9/00
CPC classification number: A61K9/5123 , A61K9/00 , A61K9/0019 , A61K9/1272 , A61K9/5146 , A61K38/177 , A61K38/1774 , A61K38/20 , A61K38/2006 , A61K38/208 , A61K38/2086 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/51 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/585 , A61P35/00 , B82Y5/00 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/5446 , C07K14/545 , C07K14/70575 , C07K2319/00 , C12N15/88 , A61K2300/00
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20230346928A1
公开(公告)日：2023-11-02
申请号：US18190453
申请日：2023-03-27
Applicant: ModernaTX, Inc.
Inventor： Joshua P. FREDERICK , Susannah HEWITT , Ailin BAI , Stephen G. HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K39/39 , A61K45/06 , A61K31/713 , A61K48/00 , A61K39/00
CPC classification number: A61K39/39558 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/705 , C07K14/70503 , C07K14/70532 , C07K14/70575 , C07K14/70596 , C07K16/2818 , A61K39/39 , A61K45/06 , A61K31/713 , A61K48/005 , A61K39/0011 , A61K2039/505 , A61K2039/53 , C07K2317/76 , C07K2319/30 , C07K2319/32 , A61K2039/585 , A61K2039/51 , A61P35/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US20210299221A1
公开(公告)日：2021-09-30
申请号：US17308686
申请日：2021-05-05
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Susannah HEWITT , Ailin BAI , Stephen HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K38/20 , A61K9/51 , C07K14/54 , A61K31/7088 , A61K31/7115 , A61K48/00 , C12N15/62 , A61P35/00 , A61K9/00
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
Patent Agency Ranking
公开(公告)号：US20200054747A1
公开(公告)日：2020-02-20
申请号：US16457300
申请日：2019-06-28
Applicant: ModernaTX, Inc.
Inventor： Joshua P. FREDERICK , Susannah HEWITT , Ailin BAI , Stephen G. HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K39/395 , A61K39/00 , A61K31/713 , A61K45/06 , A61K39/39 , C07K16/28 , C07K14/705 , C07K14/54
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US20190125839A1
公开(公告)日：2019-05-02
申请号：US16192274
申请日：2018-11-15
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Susannah HEWITT , Ailin BAI , Stephen HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
-
公开(公告)号：US20230081530A1
公开(公告)日：2023-03-16
申请号：US17275832
申请日：2019-09-13
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Sushma GURUMURTHY , Ankita MISHRA , Ailin BAI
IPC: A61K31/7105 , A61K9/51 , A61K38/17 , A61K39/395 , A61K38/20 , A61P35/00 , A61P35/02
Abstract: The disclosure features methods for treating cancer, including solid tumors and disseminated cancers such as myeloid malignancies, using one or more mRNAs encoding an OX40L polypeptide, an IL-12 polypeptide, an IL-15 polypeptide, and combinations thereof.
-
公开(公告)号：US20230041964A1
公开(公告)日：2023-02-09
申请号：US17826387
申请日：2022-05-27
Applicant: ModernaTX, Inc.
Inventor： Joshua FREDERICK , Ailin BAI , Vladimir PRESNYAK , Stephen HOGE , Kerry BENENATO , Iain MCFADYEN , Ellalahewage Sathyajith KUMARASINGHE , Susannah HEWITT
IPC: A61K9/51 , A61K48/00 , A61K38/17 , A61K38/20 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61K31/7088 , A61K31/7115 , A61P35/00 , A61K39/395
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US20220096630A1
公开(公告)日：2022-03-31
申请号：US17202829
申请日：2021-03-16
Applicant: ModernaTX, Inc.
Inventor： Joshua P. FREDERICK , Susannah HEWITT , Ailin BAI , Stephen G. HOGE , Vladimir PRESNYAK , Iain MCFADYEN , Kerry BENENATO , Ellalahewage Sathyajith KUMARASINGHE
IPC: A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K39/39 , A61K45/06 , A61K31/713 , A61K48/00 , A61K39/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.056 seconds)
